Skip to main content

Advertisement

SpringerLink
Log in

Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer

  • Original Paper
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

Pancreatic cancer is a lethal, extremely aggressive gastrointestinal tumor with a poor prognosis and limited treatment alternatives. Disulfidptosis is a newly defined type of cell death with potential influence on cancer. Research on the association between disulfidptosis and pancreatic cancer is scarce. The expression data of disulfidptosis-related genes were downloaded from The Cancer Genome Atlas-Pancreatic Adenocarcinoma (TCGA). Disulfidptosis-related lncRNA signature (DRLS) was developed through the Cox and the least absolute shrinkage and selection operator (LASSO) analysis. Differences in enrichment functions, mutational landscape, immune microenvironment, and predicted therapeutic efficacy between high- and low-risk groups were assessed. Consensus clustering analysis was applied to identify the DRLS-related subtypes. Among 98 disulfidptosis-related lncRNAs, 5 lncRNAs were screened thus constructing a prognostic DRLS. DRLS showed high predictive accuracy and was an independent prognostic factor for pancreatic cancer. According to the risk scores calculated from the signature, samples were categorized into high- and low- risk groups. Overall, low-risk patients had a better prognosis, lower mutational occurrences, higher immune cell infiltration and more sensitivity to anti-tumor agents. The DRLS performed well in predicting prognosis and revealed intimate correlation with biological function, mutation status and immune infiltration landscape of pancreatic cancer, providing some insights for future research on the relationship between disulfidptosis and pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Data Availability

Publicly available datasets can be found here: (https://portal.gdc.cancer.gov/). The datasets generated and analyzed in this study are available on request from the corresponding authors.

References

  1. Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. C Ca: A Cancer Journal for Clinicians, 73(1), 17–48.

    Google Scholar 

  2. Diaz-Cano, S. J. (2012). Tumor heterogeneity: Mechanisms and bases for a reliable application of molecular marker design. International Journal of Molecular Sciences, 13(2), 1951–2011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wang, D., Liu, B., & Zhang, Z. (2023). Accelerating the understanding of cancer biology through the lens of genomics. Cell, 186(8), 1755–1771.

    Article  CAS  PubMed  Google Scholar 

  4. Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021). Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nature Medicine, 27(2), 212–224.

    Article  CAS  PubMed  Google Scholar 

  5. Muller, S., Raulefs, S., Bruns, P., Afonso-Grunz, F., Plotner, A., Thermann, R., Jager, C., Schlitter, A. M., Kong, B., Regel, I., Roth, W. K., Rotter, B., Hoffmeier, K., Kahl, G., Koch, I., Theis, F. J., Kleeff, J., Winter, P., & Michalski, C. W. (2015). Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Molecular Cancer, 14, 94.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kisling, S. G., Atri, P., Shah, A., Cox, J. L., Sharma, S., Smith, L. M., Ghersi, D., & Batra, S. K. (2023). A Novel HOXA10-Associated 5 gene-based prognostic signature for stratification of short-term survivors of pancreatic ductal adenocarcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-23-0825

    Article  PubMed  Google Scholar 

  7. Chen, J., Liu, Z., Wu, Z., Li, W., & Tan, X. (2023). Identification of a chemoresistance-related prognostic gene signature by comprehensive analysis and experimental validation in pancreatic cancer. Frontiers in Oncology, 13, 1132424.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Chen, L., Zhang, L., He, H., Shao, F., Gao, Y., & He, J. (2023). Systemic analyses of cuproptosis-related lncRNAs in pancreatic adenocarcinoma, with a focus on the molecular mechanism of LINC00853. International Journal Of Molecular Sciences, 24(9), 7923.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ren, X., Cui, H., Wu, J., Zhou, R., Wang, N., Liu, D., Xie, X., Zhang, H., Liu, D., Ma, X., Dang, C., Kang, H., & Lin, S. (2022). Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer. Cancer Medicine, 11(20), 3886–3901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tang, R., Wu, Z., Rong, Z., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2022). Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. Briefings In Bioinformatics, 23(1), bbab388.

    Article  PubMed  Google Scholar 

  11. Yao, H. F., Xu, D. P., Zheng, J. H., Xu, Y., Jia, Q. Y., Zhu, Y. H., Yang, J., He, R. Z., Ma, D., Yang, M. W., Fu, X. L., Liu, D. J., Huo, Y. M., Yang, J. Y., & Zhang, J. F. (2023). Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Apoptosis, 28(7–8), 1090–1112.

    Article  CAS  PubMed  Google Scholar 

  12. Liu, X., Nie, L., Zhang, Y., Yan, Y., Wang, C., Colic, M., Olszewski, K., Horbath, A., Chen, X., Lei, G., Mao, C., Wu, S., Zhuang, L., Poyurovsky, M. V., James You, M., Hart, T., Billadeau, D. D., Chen, J., & Gan, B. (2023). Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nature Cell Biology, 25(3), 404–414.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhao, S., Wang, L., Ding, W., Ye, B., Cheng, C., Shao, J., Liu, J., & Zhou, H. (2023). Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework. Frontiers in Endocrinology (Lausanne), 14, 1180404.

    Article  Google Scholar 

  14. Zhang, D., Zhang, X., Liu, Z., Han, T., Zhao, K., Xu, X., Zhang, X., Ren, X., & Qin, C. (2023). An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma. Frontiers in Oncology, 13, 1207068.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Yang, L., Zhang, W., & Yan, Y. (2023). Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma. Aging (Albany NY), 15(13), 6135.

    Article  PubMed  Google Scholar 

  16. Sha, D., Jin, Z., Budczies, J., Kluck, K., Stenzinger, A., & Sinicrope, F. A. (2020). Tumor Mutational Burden as a predictive biomarker in solid tumors. Cancer Discovery, 10(12), 1808–1825.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Barthel, S., Falcomata, C., Rad, R., Theis, F. J., & Saur, D. (2023). Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. Nature Cancer, 4(4), 454–467.

    Article  PubMed  Google Scholar 

  18. Zhang, A., Miao, K., Sun, H., & Deng, C. X. (2022). Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. International Journal of Biological Sciences, 18(7), 3019–3033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zhao, K., Li, X., Shi, Y., Lu, Y., Qiu, P., Deng, Z., Yao, W., & Wang, J. (2022). A comprehensive analysis of pyroptosis-related lncRNAs signature Associated with Prognosis and Tumor Immune Microenvironment of pancreatic adenocarcinoma. Frontiers in Genetics, 13, 899496.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chi, H., Peng, G., Wang, R., Yang, F., Xie, X., Zhang, J., Xu, K., Gu, T., Yang, X., & Tian, G. (2022). Cuprotosis programmed-cell-death-related lncrna signature predicts prognosis and immune landscape in PAAD patients. Cells, 11(21), 3436.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Liu, D., Zhao, J., Wang, H., Li, H., Li, Y., & Qin, W. (2020). Long intergenic non-protein coding RNA 519 promotes the biological activities of tongue squamous cell carcinoma by sponging microRNA-876-3p and consequently upregulating MACC1. Onco Targets and Therapy, 13, 11975–11990.

    Article  CAS  Google Scholar 

  22. Ye, P., Lv, X., Aizemaiti, R., Cheng, J., Xia, P., & Di, M. (2020). H3K27ac-activated LINC00519 promotes lung squamous cell carcinoma progression by targeting miR-450b-5p/miR-515-5p/YAP1 axis. Cell Proliferation, 53(5), e12797.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Zhou, X. Y., Dai, H. Y., Zhang, H., Zhu, J. L., & Hu, H. (2022). Ferroptosis-related lncRNA for the establishment of Novel Prognostic signature and therapeutic response prediction to endometrial carcinoma. Biomed Research International, 2022, 2056913.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Jiang, K., Wu, L., Yin, X., Tang, Q., Yin, J., Zhou, Z., Yu, H., & Yan, S. (2022). Prognostic implications of necroptosis-related long noncoding RNA signatures in muscle-invasive bladder cancer. Frontiers in Genetics, 13, 1036098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Priyanka, P., Sharma, M., Das, S., & Saxena, S. (2022). E2F1-induced lncRNA, EMSLR regulates lncRNA LncPRESS1. Scientific Reports, 12(1), 2548.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Propper, D. J., & Balkwill, F. R. (2022). Harnessing cytokines and chemokines for cancer therapy. Nature Reviews. Clinical Oncology, 19(4), 237–253.

    Article  CAS  PubMed  Google Scholar 

  27. Porembka, M. R., Mitchem, J. B., Belt, B. A., Hsieh, C. S., Lee, H. M., Herndon, J., Gillanders, W. E., Linehan, D. C., & Goedegebuure, P. (2012). Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunology, Immunotherapy, 61(9), 1373–1385.

    Article  CAS  PubMed  Google Scholar 

  28. Hamarsheh, S., Gross, O., Brummer, T., & Zeiser, R. (2020). Immune modulatory effects of oncogenic KRAS in cancer. Nature Communications, 11(1), 5439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gutgemann, I., Eilers, M., & Felsher, D. W. (2016). MYC regulates the antitumor immune response through CD47 and PD-L1. Science, 352(6282), 227–231.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Nia, H. T., Munn, L. L., & Jain, R. K. (2020). Physical traits of cancer. Science, 370(6516), eaaz0868.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hartmann, N., Giese, N. A., Giese, T., Poschke, I., Offringa, R., Werner, J., & Ryschich, E. (2014). Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. Clinical Cancer Research, 20(13), 3422–3433.

    Article  CAS  PubMed  Google Scholar 

  32. Rothlin, C. V., Hille, T. D., & Ghosh, S. (2021). Determining the effector response to cell death. Nature Reviews Immunology, 21(5), 292–304.

    Article  CAS  PubMed  Google Scholar 

  33. Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020). Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. Journal of Hematology & Oncology, 13(1), 110.

    Article  Google Scholar 

  34. Kindler, H. L., Yoo, H. K., Hettle, R., Cui, K. Y., Joo, S., Locker, G. Y., & Golan, T. (2023). Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Cancer, 129(9), 1411–1418.

    Article  CAS  PubMed  Google Scholar 

  35. Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., Vincent, M., Sunakawa, Y., Dahan, L., Bajor, D., Rha, S. Y., Lemech, C., Juric, D., Rehn, M., Ngarmchamnanrith, G., Jafarinasabian, P., Tran, Q., & Hong, D. S. (2023). Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. New England Journal of Medicine, 388(1), 33–43.

    Article  CAS  PubMed  Google Scholar 

  36. Grierson, P. M., Tan, B., Pedersen, K. S., Park, H., Suresh, R., Amin, M. A., Trikalinos, N. A., Knoerzer, D., Kreider, B., Reddy, A., Liu, J., Der, C. J., Wang-Gillam, A., & Lim, K. H. (2023). Phase ib study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic adenocarcinoma. The Oncologist, 28(2), e115–e123.

    Article  PubMed  Google Scholar 

  37. Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., Ozkan-Dagliyan, I., Baldelli, E., Calvert, V., Pierobon, M., Sorrentino, J. A., Beelen, A. P., Bublitz, N., Luthen, M., Wood, K. C., Petricoin, E. F., Sers, C., McRee, A. J., Cox, A. D., & Der, C. J. (2023). Combination therapies with CDK4/6 inhibitors to treat KRAS-Mutant Pancreatic Cancer. Cancer Research, 83(1), 141–157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Javle, M., Shacham-Shmueli, E., Xiao, L., Varadhachary, G., Halpern, N., Fogelman, D., Boursi, B., Uruba, S., Margalit, O., Wolff, R. A., & Golan, T. (2021). Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: Findings from 2 phase 2 Nonrandomized clinical trials. JAMA Oncology, 7(5), 693–699.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We appreciate all the participants and researchers for their contributions and commitment to this study.

Funding

This work was jointly supported by the National Natural Science Foundation of China (No. 82173178, U21A20374), Shanghai Municipal Science and Technology Major Project (21JC1401500), Scientific Innovation Project of Shanghai Education Committee (2019-01-07-00-07-E00057), Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR1006A), and Xuhui District Artificial Intelligence Medical Hospital Cooperation Project (2021-011).

Author information

Authors and Affiliations

  1. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China

    Faliang Xing, Yi Qin, Jin Xu, Wei Wang & Bo Zhang

  2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

    Faliang Xing, Yi Qin, Jin Xu, Wei Wang & Bo Zhang

  3. Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China

    Faliang Xing, Yi Qin, Jin Xu, Wei Wang & Bo Zhang

  4. Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China

    Faliang Xing, Yi Qin, Jin Xu, Wei Wang & Bo Zhang

Authors
  1. Faliang Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wei Wang or Bo Zhang.

Ethics declarations

Competing interests

The authors declare that they have no competing interests.

Ethical Approval

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 125.0 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xing, F., Qin, Y., Xu, J. et al. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. Mol Biotechnol (2023). https://doi.org/10.1007/s12033-023-00875-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12033-023-00875-z

Keywords

Search

Navigation